SCHEMBL17205222

SCHEMBL17205222

Cc1cc(C)c2c(C(=O)NC3CCCCCCC3)c[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 2/20 0.58
▸ TAS1R1 Q7RTX1 2/20 0.58
▸ TAS1R2 Q8TE23 2/20 0.58
▸ BACE1 P56817 1/20 0.51
▸ NPC1 O15118 4/20 0.50
▸ RAB9A P51151 4/20 0.50
▸ TP53 P04637 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ KMT2A Q03164 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ ADORA2A P29274 1/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206332 1.00 TAS1R3 (0.58) TAS1R3TAS1R1TAS1R2BACE1NPC1
SCHEMBL17206300 0.79 CNR2 (0.42) SMN1; SMN2KMT2AALDH1A1MEN1L3MBTL1
SCHEMBL17209758 0.78 NR4A2 (0.41) NPC1RAB9ATP53MAPTPOLB
SCHEMBL18520224 0.75 KCNQ3 (0.42) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL22754845 0.74 NPC1 (0.50) TAS1R3TAS1R1TAS1R2BACE1NPC1
SCHEMBL16610119 0.74 ALDH1A1 (0.57) BACE1NPC1RAB9ATP53MAPT
SCHEMBL704712 0.74 TAS1R3 (1.00) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL701293 0.74 TAS1R3 (1.00) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL14512826 0.74 TAS1R3 (1.00) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL8210918 0.74 NPC1 (0.74) TAS1R3TAS1R1TAS1R2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS UNIV JOHNS HOPKINS (US) 2017-02-16 — — US disclosed
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS UNIV JOHNS HOPKINS (US) 2017-02-16 — — US disclosed
WO-2016171743-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2016-10-27 — — WO disclosed
WO-2016171743-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2016-10-27 — — WO disclosed
WO-2015164482-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2015-10-29 — — WO disclosed
WO-2015164482-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2015-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS IDO2, IDO1, INMT TAS1R3 4529/4885TAS1R1 4601/4885TAS1R2 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback